Doctor Abandons US Patent Application
By Solomon Times,
Solomon Times
| 04. 11. 2011
The patent application was launched by US based lawyers on behalf of Taiwanese scientist, Dr Ko Ying-Chin.
According to the US Patent Application Information Retrieval system, US based lawyers representing Taiwanese scientist, Dr Ko Ying-Chin, have since filed an express abandonment application on the first of this month for the patent application number.
NIPS says the express abandonment was subsequently processed by the US body on Monday this week and now the status of the US patent application is listed as "expressly abandoned.
Effectively, the patent application is now stopped.
This patent application entitled "Method and Kit for Assessing Risk of Gout and Hyperuricemia," uses samples from 192 Solomon Islanders, collected at the National Referral Hospital and two clinics in Guadalcanal Province during a research trip led by Dr Ko in September 2006.
Dr Ko and his colleagues only abandoned the patent application after NIPS, along with other non-governmental organizations in the Solomon Islands, began to publicly challenge it.
The basis of this challenge was Dr Ko's failure to obtain proper informed consent from the blood donors for such commercialization.
Related Articles
By Pallab Gosh and Gwyndaf Hughes, BBC News | 06.26.2025
Work has begun on a controversial project to create the building blocks of human life from scratch, in what is believed to be a world first.
The research has been taboo until now because of concerns it could lead to...
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...